Abstract
Purpose
In an era of personalised medicine, there is an overwhelming effort for predicting patients who will benefit from extended radical resections for locally advanced pelvic malignancy. However, there is paucity of data on the effect of comorbidities and postoperative complications on long-term overall survival (OS). The aim of this study was to define predictors of 1-year and 5-year OS.
Methods
Data were collected from prospective databases at two high-volume institutions specialising in beyond TME surgery for locally advanced and recurrent pelvic malignancies between 1990 and 2015. The primary outcome measures were 1-year and 5-year OS.
Results
A total of 646 consecutive extended radical resections were performed between 1990 and 2015. The majority were female patients (371, 57.4%) and the median age was 63 years (range 19–89 years). One-year OS, primary rectal adenocarcinoma had the best survival while recurrent colon cancer had the worse survival (p = 0.047). The 5-year OS between primary and recurrent cancers were 64.7% and 53%, respectively (p = 0.004). Poor independent prognostic markers for 5-year OS were increasing ASA score, cardiovascular disease, recurrent cancers, ovarian cancers, pulmonary embolus and acute respiratory distress syndrome. A positive survival benefit was demonstrated with preoperative radiotherapy (HR 0.55; 95% CI 0.4–0.75, p < 0.001).
Conclusion
Patient comorbidities and specific complications can influence long-term survival following extended radical resections. This study highlights important predictors, enabling clinicians to better inform patients of the potential short- and long-term outcomes in the management of locally advanced and recurrent pelvic malignancy.
Similar content being viewed by others
References
Brunschwig A (1948) Complete excision of pelvic viscera for advanced carcinoma; a one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy. Cancer 1(2):177–183
Brunschwig A, Daniel W (1960) Pelvic exenteration operations: with summary of sixty-six cases surviving more than five years. Ann Surg 151:571–576
Radwan RW, Jones HG, Rawat N, Davies M, Evans MD, Harris DA, Beynon J, Swansea Pelvic Oncology Group (2015) Determinants of survival following pelvic exenteration for primary rectal cancer. Br J Surg 102(10):1278–1284
Morley GW, Hopkins MP, Lindenauer SM, Roberts JA (1989) Pelvic exenteration, University of Michigan: 100 patients at 5 years. Obstet Gynecol 74(6):934–943
Westin SN, Rallapalli V, Fellman B, Urbauer DL, Pal N, Frumovitz MM, Ramondetta LM, Bodurka DC, Ramirez PT, Soliman PT (2014) Overall survival after pelvic exenteration for gynecologic malignancy. Gynecol Oncol 134(3):546–551
Steffens D, Solomon MJ, Young JM, Koh C, Venchiarutti RL, Lee P, Austin K (2018) Cohort study of long-term survival and quality of life following pelvic exenteration. BJS Open 2(5):328–335
You YN, Skibber JM, Hu C-Y, Crane CH, Das P, Kopetz ES, Eng C, Feig BW, Rodriguez-Bigas MA, Chang GJ (2016) Improved long-term salvage potential of locally recurrent rectal cancer with evolving multimodality therapy. Br J Surg 103(6):753–762
Georgiou PA, Tekkis PP, Constantinides VA, Patel U, Goldin RD, Darzi AW, John Nicholls R, Brown G (2013) Diagnostic accuracy and value of magnetic resonance imaging (MRI) in planning exenterative pelvic surgery for advanced colorectal cancer. Eur J Cancer 49(1):72–81
Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213
Berrios-Torres SI, Umscheid CA, Bratzler DW, Leas B, Stone EC, Kelz RR et al (2017) Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg 152(8):784–791
Rahbari NN, Weitz J, Hohenberger W, Heald RJ, Moran B, Ulrich A, Holm T, Wong WD, Tiret E, Moriya Y, Laurberg S, den Dulk M, van de Velde C, Büchler MW (2010) Definition and grading of anastomotic leakage following anterior resection of the rectum: a proposal by the International Study Group of Rectal Cancer. Surgery 147(3):339–351
Wagenlehner FM, Pilatz A, Naber KG, Weidner W (2008) Therapeutic challenges of urosepsis. Eur J Clin Investig 38(Suppl 2):45–49
Kreiner L (2018) Intra-abdominal collection: BMJ. Available from: https://bestpractice.bmj.com/topics/en-gb/996
Quirke P, Steele R, Monson J, Grieve R, Khanna S, Couture J, O'Callaghan C, Myint AS, Bessell E, Thompson LC, Parmar M, Stephens RJ, Sebag-Montefiore D, MRC CR07/NCIC-CTG CO16 Trial Investigators, NCRI Colorectal Cancer Study Group (2009) MRC CR07/NCIC-CTG CO16 Trial Investigators; NCRI Colorectal Cancer Study Group. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 373:821–828
Nagtegaal ID, Quirke P (2008) What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 26:303–312
Wibe A (2002) Moller B; A national strategic change in treatment policy for rectal cancer—implementation of total mesorectal excision as routine treatment in Norway. Dis Colon Rectum 45:857–866
Ortiz H (2013) Impact of a multidisciplinary team training programme on rectal cancer outcomes in Spain. Color Dis 15:544–551
West NP, Sutton KM, Ingeholm P, Hagemann-Madsen RH, Hohenberger W, Quirke P (2010) Improving the quality of colon cancer surgery through a surgical education program. Dis Colon Rectum 53:1594–1603
Khan MA (2015) Significance of R1 resection margin in colon cancer resections in the modern era. Color Dis 17:943–953
Seymour MT, Morton D, on behalf of the International FOxTROT Trial Investigators (2019) FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. J Clin Oncol 37(15_suppl):3504–3350
Ferenschild FTJ, Vermaas M, Verhoef C, Ansink AC, Kirkels WJ, Eggermont AMM, de Wilt JHW (2009) Total pelvic exenteration for primary and recurrent malignancies. World J Surg 33(7):1502–1508
Gannon CJ, Zager JS, Chang GJ, Feig BW, Wood CG, Skibber JM, Rodriguez-Bigas MA (2007) Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma. Ann Surg Oncol 14(6):1870–1877
Kuhrt MP, Chokshi RJ, Arrese D, Martin EW Jr (2012) Retrospective review of pelvic malignancies undergoing total pelvic exenteration. World J Surg Oncol 10(1):110
Klok FA, Zondag W, Kralingen KW, Dijk APJ, Tamsma JT, Heyning FH et al (2010) Patient Outcomes after Acute Pulmonary Embolism. Am J Respir Crit Care Med 181(5):501–506
White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Henley SJ (2014) Age and cancer risk: a potentially modifiable relationship. Am J Prev Med 46(3 0 1):S7–S15
Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Maas HA, Coebergh JW (2005) Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol 55(3):231–240
Kong CH, Guest GD, Stupart DA, Faragher IG, Chan ST, Watters DA (2015) Colorectal preOperative Surgical Score (CrOSS) for mortality in major colorectal surgery. ANZ J Surg 85(6):403–407
Janssen-Heijnen ML, Szerencsi K, van de Schans SA, Maas HA, Widdershoven JW, Coebergh JW (2010) Cancer patients with cardiovascular disease have survival rates comparable to cancer patients within the age-cohort of 10 years older without cardiovascular morbidity. Crit Rev Oncol Hematol 76(3):196–207
Tashakkor AY, Moghaddamjou A, Chen L, Cheung WY (2013) Predicting the risk of cardiovascular comorbidities in adult cancer survivors. Curr Oncol 20(5):e360–ee70
Des Guetz G (2010) Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer 46:1049–1055
Bosset J-F (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123
Harris CA, Solomon MJ, Heriot AG, Sagar PM, Tekkis PP, Dixon L, Pascoe R, Dobbs BR, Frampton CM, Harji DP, Kontovounisios C, Austin KK, Koh CE, Lee PJ, Lynch AC, Warrier SK, Frizelle FA (2016) The outcomes and patterns of treatment failure after surgery for locally recurrent rectal cancer. Ann Surg 264(2):323–329
Lau YC, Jongerius K, Wakeman C, Heriot AG, Solomon MJ, Sagar PM, Tekkis PP, Frizelle FA (2019) Influence of the level of sacrectomy on survival in patients with locally advanced and recurrent rectal cancer. Br J Surg 106(4):484–490
Funding
None
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Conflict of Interest
The authors declare that they have no competing interests.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Joseph C. Kong and Oliver Peacock are co-first authors.
Rights and permissions
About this article
Cite this article
Kong, J.C., Peacock, O., Waters, P.S. et al. Predictors of overall survival following extended radical resections for locally advanced and recurrent pelvic malignancies. Langenbecks Arch Surg 405, 491–502 (2020). https://doi.org/10.1007/s00423-020-01895-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00423-020-01895-y